BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 26494524)

  • 1. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.
    Trenkwalder C; Chaudhuri KR; Martinez-Martin P; Rascol O; Ehret R; Vališ M; Sátori M; Krygowska-Wajs A; Marti MJ; Reimer K; Oksche A; Lomax M; DeCesare J; Hopp M;
    Lancet Neurol; 2015 Dec; 14(12):1161-70. PubMed ID: 26494524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.
    Trenkwalder C; Beneš H; Grote L; García-Borreguero D; Högl B; Hopp M; Bosse B; Oksche A; Reimer K; Winkelmann J; Allen RP; Kohnen R;
    Lancet Neurol; 2013 Dec; 12(12):1141-50. PubMed ID: 24140442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial.
    Leng X; Zhang F; Yao S; Weng X; Lu K; Chen G; Huang M; Huang Y; Zeng X; Hopp M; Lu G
    Adv Ther; 2020 Mar; 37(3):1188-1202. PubMed ID: 32020565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.
    Löwenstein O; Leyendecker P; Hopp M; Schutter U; Rogers PD; Uhl R; Bond S; Kremers W; Nichols T; Krain B; Reimer K
    Expert Opin Pharmacother; 2009 Mar; 10(4):531-43. PubMed ID: 19243306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1528-1537. PubMed ID: 28641363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1485-1494. PubMed ID: 28474460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives.
    Koopmans G; Simpson K; De Andrés J; Lux EA; Wagemans M; Van Megen Y
    Curr Med Res Opin; 2014 Nov; 30(11):2389-96. PubMed ID: 25265132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension.
    Oertel WH; Hallström Y; Saletu-Zyhlarz GM; Hopp M; Bosse B; Trenkwalder C;
    CNS Drugs; 2016 Aug; 30(8):749-60. PubMed ID: 27401882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation.
    Poelaert J; Koopmans-Klein G; Dioh A; Louis F; Gorissen M; Logé D; Van Op den Bosch J; van Megen YJ
    Clin Ther; 2015 Apr; 37(4):784-92. PubMed ID: 25757607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.
    Vondrackova D; Leyendecker P; Meissner W; Hopp M; Szombati I; Hermanns K; Ruckes C; Weber S; Grothe B; Fleischer W; Reimer K
    J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.
    Meissner W; Leyendecker P; Mueller-Lissner S; Nadstawek J; Hopp M; Ruckes C; Wirz S; Fleischer W; Reimer K
    Eur J Pain; 2009 Jan; 13(1):56-64. PubMed ID: 18762438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain.
    Madeo G; Schirinzi T; Natoli S; Pierantozzi M; Stefani A; Dauri M; Pisani A
    J Neurol; 2015 Sep; 262(9):2164-70. PubMed ID: 26134157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
    Ueberall MA; Mueller-Schwefe GH
    Curr Med Res Opin; 2015; 31(7):1413-29. PubMed ID: 25942606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.
    Ahmedzai SH; Nauck F; Bar-Sela G; Bosse B; Leyendecker P; Hopp M
    Palliat Med; 2012 Jan; 26(1):50-60. PubMed ID: 21937568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged-release oxycodone/naloxone in postoperative pain management: from a randomized clinical trial to usual clinical practice.
    Kuusniemi K; Zöllner J; Sjövall S; Huhtala J; Karjalainen P; Kokki M; Lemken J; Oppermann J; Kokki H
    J Int Med Res; 2012; 40(5):1775-93. PubMed ID: 23206459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis.
    Dunlop W; Uhl R; Khan I; Taylor A; Barton G
    J Med Econ; 2012; 15(3):564-75. PubMed ID: 22313329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of oxycodone-naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study.
    Guerriero F; Roberto A; Greco MT; Sgarlata C; Rollone M; Corli O
    Drug Des Devel Ther; 2016; 10():1515-23. PubMed ID: 27143857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials.
    Blagden M; Hafer J; Duerr H; Hopp M; Bosse B
    Neurogastroenterol Motil; 2014 Dec; 26(12):1792-801. PubMed ID: 25346155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.
    Lazzari M; Greco MT; Marcassa C; Finocchi S; Caldarulo C; Corli O
    Drug Des Devel Ther; 2015; 9():5863-72. PubMed ID: 26586937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice.
    Schutter U; Grunert S; Meyer C; Schmidt T; Nolte T
    Curr Med Res Opin; 2010 Jun; 26(6):1377-87. PubMed ID: 20380506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.